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Purpose and Scope
Drug and Alcohol Dependence is an international journal devoted to publishing original research, scholarly reviews, commentaries, and policy analyses in the areas of
drug, alcohol, and tobacco use and dependence. Articles range from studies of the chemistry of substances of abuse, their actions at molecular and cellular sites, in vitro
and in vivo investigations of their biochemical, pharmacological, and behavioral actions, laboratory-based and clinical research in humans, substance abuse treatment and
prevention research, to studies employing methods from epidemiology, sociology, and economics. The rationale for this extensive coverage is the conviction that drug,
alcohol, and tobacco use/dependence cannot be understood in their entirety from a single perspective and that without an understanding of other areas of research, studies
by individual investigators may be limited. The goal of the journal is to provide researchers, clinicians, and policy makers access to material from all perspectives in a
single journal in a format that is understandable and which has received rigorous editorial review. The hope of its Editors is to promote mutual understanding of the many
facets of drug abuse to the beneﬁ t of all investigators involved in drug and alcohol research, and to facilitate the transfer of scientiﬁ c ﬁ ndings to successful treatment and
prevention practices. Drug and Alcohol Dependence is currently being distributed to all the members of The College on Problems of Drug Dependence, the oldest
scientiﬁ c organization in the United States concerned with the research on problems of drug dependence.
Types of Papers
 1. Full-length Reports reporting original results of research within the ﬁ eld of drug, alcohol and tobacco use and dependence.
 2. Review Articles of specialised topics within the scope of the journal. Authors who plan to submit reviews to the journal are advised to contact one of the editors to
discuss the suitability of the proposed topic.
 3. Short Communications reporting on research that has progressed to the stage where a preliminary publication is appropriate. The maximum length allowed will be
1500 words plus references and illustrations. There should be not more than 2 illustrations (ﬁ gures or tables).
Drug and Alcohol Dependence is a signatory of the Farmington Consensus Statement which is published in its entirety in Volume 48 Issue 3. Submission of a paper to
the journal will be taken as evidence that the authors have complied with the tenets set forth in that statement. When articles are submitted, a written statement that each
listed author has contributed substantially to the work and concurs with the submission should be included. This implies that a copy of the ﬁ nal manuscript has been
approved by all authors and tacitly and explicitly by the responsible authorities in the laboratories where the work was carried out. Authors should also assure the journal
in a written statement that there is no known conﬂ ict of interest. If authors have any questions concerning a possible conﬂ ict of interest, they should consult the Editor
prior to submission. Authors should reveal explicitly in the manuscript all funding sources that enabled the studies to be conducted and the manuscript prepared, and that
the study was conducted with the appropriate ethical safeguards. Submission of a paper to Drug and Alcohol Dependence is also understood to imply that it has not
previously been published and that it is not being published elsewhere, including in electronic form. The accepted abbreviation for Drug and Alcohol Dependence for
bibliography citation is Drug Alcohol Depend. If accepted, the manuscript shall not be published elsewhere in the same form or electronically, in either the same or
another language, without the consent of the Editor and Publisher. Authors should be aware that the journal has deﬁ ned policies for response to attempted or actual
instances of duplicate publication, plagiarism, or scientiﬁ c fraud.
Editor-in-Chief: Eric C. Strain, M.D.,
Johns Hopkins University School of Medicine




Craig R. Rush, Ph.D.,
University of Kentucky
Comorbidity, Psychiatric Epidemiology, Etiology, Nosology and Genetics
Katherine M. Keyes, Ph.D.,
Columbia University
Etiology, Epidemiology, Prevention and Policy
Steffanie A. Strathdee, Ph.D.,
University of California, San Diego
Steven Shoptaw, Ph.D.,
University of California, Los Angeles
Human Psychopharmacology and Genetics
Eske Derks, Ph.D.,
Academic Medical Center, Amsterdam 
Neuropsychopharmacology and Treatment
Lin Lu, M.D., Ph.D.,
Peking University
Preclinical and Clinical Neurosciences
Linda Porrino, Ph.D., 
Wake Forest University School of Medicine
Services and Prevention, Technology Transfer, and 
Treatment
Jan Copeland, Ph.D.,
University of New South Wales
Tobacco and Nicotine, Health Disparities, Developmental 
Psychopathology
Adam M. Leventhal, Ph.D.,





F.J. Alvarez, Valladolid, Spain
J.C. Anthony, East Lansing, USA
M. Auriacombe, Bordeaux, France
R.L. Balster, Richmond, VA, USA
F.I.P.M. Bastos, Rio de Janeiro, Brazil
W.K. Bickel, Roanoke, VA, USA
K.T. Brady, Charleston, SC, USA
Z.D. Cooper, New York, New York, USA
J.F. Cubells, Atlanta, GA, USA
S. Darke, Kensington, NSW, Australia
L.C. Dierker, Middletown, CT, USA
M.E. Ensminger, Baltimore, MD, USA
M. Farré, Barcelona, Spain
M. Field, Liverpool, UK
P.M. Flynn, Ft. Worth, TX, USA
I.H.A. Franken, Rotterdam, The Netherlands
B.F. Grant, Rockville, MD, USA
O. Gureje, Ibadan, Nigeria
D.S. Hasin, New York, New York, USA
D.K. Hatsukami, Minneapolis, MN, USA
J.R. Havens, Lexington, Kentucky, USA
M.Y. Iguchi, Santa Monica, CA, USA
J. Kitanaka, Hyogo, Japan
H.R. Kranzler, Farmington, CT, USA
R.J. Lamb, San Antonio, TX, USA
S. Lukas, Belmont, MA, USA
A.T. McLellan, Philadelphia, PA, USA
M.E. Medina-Mora, Mexico City, Mexico
F.G. Moeller, Richmond, Virginia, USA
M. Munafò, Bristol, UK
T.C. Napier, Chicago, IL, USA
I.S. Obot, Geneva, Switzerland
V.R. Preedy, London, UK
K.L. Preston, Baltimore, MD, USA
A.J. Saxon, Seattle, WA, USA
J.L. Sorensen, San Francisco, CA, USA
I.P. Stolerman, London, UK
J. Strang, London, UK
D. Svikis, Richmond, VA, USA
R. Tarter, Pittsburgh, PA, USA
W. van den Brink, Amsterdam, 
 The Netherlands
S.L. Walsh, Lexington, KY, USA







© 2016, Elsevier Ireland Ltd. All rights reserved.
Publication information: Drug and Alcohol Dependence (ISSN 0376-8716). For 2016 Volumes 158–169 are scheduled for publication. Subscription prices are available
upon request from the Publisher or from the Elsevier Customer Service Department nearest you or from this journal’s website (http://www.elsevier.com/locate/drugalcdep). Further
information is available on this journal and other Elsevier products through Elsevier’s website: (http://www.elsevier.com). Subscriptions are accepted on a prepaid basis
only and are entered on a calendar year basis. Issues are sent by standard mail (surface within Europe, air delivery outside Europe). Priority rates are available upon
request. Claims for missing issues should be made within six months of the date of dispatch.
Drug and Alcohol Dependence proceeds entirely online at http://ees.elsevier.com/dad
This site also links you directly through to other author services, such as: Artwork Instructions,
Copyright Information, Language Editing, Track your paper, Scirus, ScienceDirect
ADVERTISING INFORMATION: Advertising orders and inquiries can be sent to: USA, Canada and South America: Elsevier Inc., 360 Park Avenue South, New York, NY 
10010-1710, USA; phone: (+1) (212) 633 3974; Europe and ROW: 125 London Wall, London, EC2Y 5AS, United Kingdom; phone: +44 (0) 20 7424 4200; fax: +44 (0) 20 7424 4431; 
e-mail: AdvertisingHSSales@elsevier.com
USA mailing notice: Drug and Alcohol Dependence (ISSN 0376-8716) is published monthly by Elsevier Ireland Ltd., Elsevier House, Brookvale Plaza, East Park, Shannon, Co. Clare, Ireland. 
Periodicals postage paid at Jamaica, NY 11431 and additional mailing oﬃ  ces.
USA POSTMASTER: Send change of address to Drug and Alcohol Dependence, Elsevier Customer Service Department, 3251 Riverport Lane, Maryland Heights, MO 63043, USA. 
AIRFREIGHT AND MAILING in the USA by Air Business Ltd., c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.
Orders, claims, and journal inquiries: please contact the Elsevier Customer Service Department nearest you:
St. Louis: Elsevier Customer Service Department, 3251 Riverport Lane, Maryland Heights, MO 63043, USA; phone: (800) 6542452 [toll free within the USA]; (+1) (314) 4478871 
[outside the USA]; fax: (+1) (314) 4478029; e-mail: JournalCustomerService-usa@elsevier.com 
Oxford: Elsevier Customer Service Department, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK; phone: (+44) (1865) 843434; fax: (+44) (1865) 843970; e-mail: 
JournalsCustomerServiceEMEA@elsevier.com
Tokyo: Elsevier Customer Service Department, 4F Higashi-Azabu, 1-Chome Bldg, 1-9-15 Higashi-Azabu, Minato-ku, Tokyo 106-0044, Japan; phone: (+81) (3) 5561 5037; 
fax: (+81) (3) 5561 5047; e-mail: JournalsCustomerServiceJapan@elsevier.com
Singapore: Elsevier Customer Service Department, 3 Killiney Road, #08-01 Winsland House I, Singapore 239519; phone: (+65) 63490222; fax: (+65) 67331510; e-mail: 
JournalsCustomerServiceAPAC@elsevier.com
Author inquiries: You can track your submitted article at http://www.elsevier.com/track-submission. You can track your accepted article at http://www.elsevier.com/trackarticle. You 
are also welcome to contact Customer Support via http://support.elsevier.com
Language (Usage and Editing services): Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language 
manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientiﬁ c English may wish to use the English Language Editing service 
available from Elsevier’s WebShop http://webshop.elsevier.com/languageediting/ or visit our customer support site http://support.elsevier.com for more information. 
Illustration services: Elsevier’s WebShop (http://webshop.elsevier.com/illustrationservices) offers Illustration Services to authors preparing to submit a manuscript but concerned 
about the quality of the images accompanying their article. Elsevier’s expert illustrators can produce scientiﬁ c, technical and medical-style images, as well as a full range of charts, 
tables and graphs. Image ‘polishing’ is also available, where our illustrators take your image(s) and improve them to a professional standard. Please visit the website to ﬁ nd out more.
Funding body agreements and policies : Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to 
comply with potential manuscript archiving requirements as speciﬁ ed as conditions of their grant awards. To learn more about existing agreements and policies please visit 
http://www.elsevier.com/fundingbodies
  The paper used in this publication meets the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper)
Notes To Authors
For a full and complete Guide for Authors, please go to: http://www.elsevier.com/locate/drugalcdep
DAD Fellow
Joseph Palamar, Ph.D., MPH, 
New York University 
Processed at Thomson Digital, Gangtok (India)
